Roth Capital Starts Fate Therapeutics (FATE) at Buy
Tweet
Share
E-mailGet Alerts FATE Hot Sheet
Price: $3.10 -0.32%
Rating Summary:
11 Buy, 13 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 11 | New: 17
Rating Summary:
11 Buy, 13 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 11 | New: 17
Join SI Premium – FREE
Roth Capital initiated coverage on Fate Therapeutics (NASDAQ: FATE) with a Buy rating and a price target of $8.00.
For an analyst ratings summary and ratings history on Fate Therapeutics click here. For more ratings news on Fate Therapeutics click here.
Shares of Fate Therapeutics closed at $3.18 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H.C. Wainwright Reiterates Buy Rating on Fate Therapeutics (FATE)
- Edgewater Research Starts Parker-Hannifin (PH) at Neutral
- Nomura/Instinet Reinstates Shin-Etsu Chemical Co Ltd. (4063:JP) (SHECY) at Neutral
Create E-mail Alert Related Categories
New CoverageRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
